New, noninvasive blood-plasma based methods to follow the genetic and molecular evolution of solid tumors in patients are emerging. These technologies detect mutations in circulating tumor DNA, allowing monitoring of tumor changes over time. George D. Demetri, HMS professor of medicine at the Dana-Farber Cancer Institute, is one of the lead researchers.
